GEMIN2: A Potential Drug Target and Biomarker for Survival of Motor Neuron Protein Interacting Protein 1

Target Name: GEMIN2

NCBI ID: G8487

GEMIN2

GEMIN2: A Potential Drug Target and Biomarker for Survival of Motor Neuron Protein Interacting Protein 1

Survival of Motor Neuron Protein (SMN) is a critical protein that plays a crucial role in the survival and integrity of motor neurons. It is composed of four isoforms: SMN1, SMN2, SMN3, and SMN4, which differ in their length and sequence. SMN1 is the most abundant isoform, and it is responsible for the majority of SMN protein in the brain. The SMN protein is composed of 176 amino acid residues, and it has a critical role in the development, maintenance, and repair of motor neurons.

SMN has been linked to various neurological disorders, including spinal muscular atrophy (SMA), a genetic disorder that affects muscle strength and function. SMA is caused by a deficiency of dystrophin, a protein that helps keep SMN levels in balance. SMN interacts with dystrophin to regulate the stability of SMN protein and maintain its levels in the brain.

GEMIN2: A Potential Drug Target and Biomarker

GEMIN2 is a protein that interacts with SMN1 and has been identified as a potential drug target for SMA. GEMIN2 is a 21-kDa protein that is composed of 116 amino acid residues. It has a critical role in the regulation of cellular processes, including cell adhesion, migration, and survival. GEMIN2 has also been shown to interact with other proteins, including SMN1, and it may be a useful biomarker for SMA.

GEMIN2 has been shown to promote the expression of SMN1 in various cell types, including human embryonic stem cells and primary motor neuron cells. This may be a potential mechanism by which GEMIN2 could be used to treat SMA.

Another potential mechanism by which GEMIN2 could be used to treat SMA is by increasing the stability of SMN protein in the brain. SMN has been shown to be unstable in the brain and to undergo degradation, which may contribute to the development of SMA. By interacting with GEMIN2, SMN1 may be able to stability its levels in the brain and reduce the risk of neurodegeneration.

GEMIN2 may also be a useful biomarker for monitoring the effectiveness of SMA treatments. The levels of GEMIN2 may be able to be used as a marker for the expression of SMN1 and for the effectiveness of SMA treatments.

Conclusion

GEMIN2 is a protein that has been shown to interact with SMN1 and may be a potential drug target for SMA. Its role in the regulation of cellular processes and its potential ability to promote the expression of SMN1 in various cell types make it an attractive candidate for use as a drug. Additionally, GEMIN2 may be a useful biomarker for monitoring the effectiveness of SMA treatments. Further research is needed to fully understand the role of GEMIN2 in SMA and to develop effective treatments.

Protein Name: Gem Nuclear Organelle Associated Protein 2

Functions: The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9323129). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG (5Sm) are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A (PubMed:18984161, PubMed:9323129). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP (PubMed:31799625). Within the SMN complex, GEMIN2 constrains the conformation of 5Sm, thereby promoting 5Sm binding to snRNA containing the snRNP code (a nonameric Sm site and a 3'-adjacent stem-loop), thus preventing progression of assembly until a cognate substrate is bound (PubMed:31799625, PubMed:21816274, PubMed:16314521)

The "GEMIN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GEMIN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets